[Fam-] Trastuzumab Deruxtecan in Advanced Gastric Cancer With Kohei Shitara, MD

​ Current treatment options are highly limited for patients with advanced human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction cancer, particularly after trastuzumab. A potential new treatment has emerged in a phase 1 clinical trial, which reports that [fam-] trastuzumab deruxtecan shows preliminary activity in patients with heavily pretreated HER2-positive gastric or gastro-esophageal junction cancer. In this interview with i3 Health, Kohei Shitara, MD,...
Continue reading

Advanced Gastric Cancer: [Fam-] Trastuzumab Deruxtecan Shows Promise

A phase 1 clinical trial reports that [fam-] trastuzumab deruxtecan shows preliminary activity in patients with heavily pretreated human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction cancer. "These results are encouraging given the limited options for patients with advanced HER2-positive gastric cancer that progresses after initial treatment regimens including trastuzumab," commented Kohei Shitara, MD, Chief of the Department of Experimental Therapeutic...
Continue reading

Therapeutic Target Found in MSI-High Tumors

​ Microsatellite instability (MSI), characteristic variations in the length of tandem nucleotide repeats across the genome, has been seen in a wide variety of cancers, including colon cancer, gastric cancer, endometrium cancer, ovarian cancer, hepatobiliary tract cancer, urinary tract cancer, brain cancer, and skin cancers. Researchers' discovery of the important role played by Werner syndrome helicase (WRN) in MSI-high (MSI-H) tumors presents a new opportunity for the development of targeted th...
Continue reading

New Therapeutic Targets Found in Esophageal Cancer

​ Esophageal adenocarcinoma (EAC), the most common type of esophageal cancer, is highly deadly, with only 20% of patients surviving five years from diagnosis. It is resistant to standard chemoradiotherapy treatments and has few targeted therapies. "Targeted therapies are virtually non-existent," remarked Kishore Guda, DVM, PhD, Associate Professor in the Case Comprehensive Cancer Center of Case Western Reserve University. "Treatment advancements are also slowed because we don't know exactly what...
Continue reading

Heavily Pretreated Metastatic Gastric Cancer: Dr. Kohei Shitara on Trifluridine/Tipiracil Approval

The FDA's recent approval of trifluridine/tipiracil tablets (Lonsurf®, Taiho Pharmaceutical Co., Ltd.) for heavily pretreated metastatic gastric adenocarcinoma and gastroesophageal junction adenocarcinoma represents a significant development for patients with gastric cancer, the third most frequent cause of cancer-related death. In this interview with i3 Health, Kohei Shitara, MD, speaks about the significance of this approval. Dr. Shitara was the lead author of the phase 3 TAGS study (NCT0...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.